生物制药与制药应用

预后/预测标志物开发

因美纳药物开发解决方案

TruSight Oncology 500

TruSight Oncology 500系列产品包括三种检测方法，可通过泛癌全景变异分析（CGP） 对血液或组织活检样本中的实体瘤进行精准肿瘤学分析。该系列产品可用于识别各项指南和临床研究中的相关生物标志物，如TMB、MSI和HRD。TruSight Oncology 500 检测评估FFPE肿瘤组织中的相关DNA和RNA癌症生物标志物（现可通过配套试剂盒支持检测HRD），可评估基因组不稳定性评分（GIS）。

TruSight Oncology 500高通量检测使用与TruSight Oncology 500检测相同的组织类型时，一次最多可批量检测192份样本。TruSight Oncology 500 ctDNA检测使用TruSight Oncology 500 ctDNA检测分析血浆中的循环肿瘤DNA。该系列产品集多项卓越特性于一身，具有强大的综合基因组图谱分析能力，试剂盒能够无缝融入您的实验室环境，通过提供集成化、高灵活性及可扩展性的工作流程，确保能够迅速获取及时且可靠的研究结果。

TruSight Oncology 500
TruSight Oncology 500产品系列

参考文献

  1. llumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics.
    https://www.businesswire.com/news/home/20180410005649/en​
  2. As Lilly deal closes, Bayer secures full rights to Loxo's Vitrakvi
    https://www.biopharmadive.com/news/as-lilly-deal-closes-bayer-secures-full-rights-to-loxos-vitrakvi/548584/
  3. Roche, Illumina Partner on Next-Generation Sequencing IVD, CDx Development, Marketing.
    https://www.genomeweb.com/business-news/roche-illumina-partner-next-generation-sequencing-ivd-cdx-development-marketing#.Xla-RqhKjIU​
  4. Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling:
    https://sapac.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=c8606ce8-c9ec-4c7f-9659-270952ae7bba 
  5. Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic:
    https://www.illumina.com/company/news-center/press-releases/2021/12b6e4a6-3f52-407e-8200-8fa72712a980.html
  6. Illumina, Janssen Biotech Form Strategic Partnership to Develop Precision Medicines
    https://www.genomeweb.com/sequencing/illumina-janssen-biotech-form-strategic-partnership-develop-precision-medicines#.Yn7P_trMI2w​

了解更多

药企合作举例——药物研发临床研究中的TSO CDx开发